Skip to main content
OpenTrials
Completed

NCT Number: NCT06709820

A Study of LY4060874 in Healthy Participants

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.

Study participation may last up to 22 weeks and up to approximately 18 study visits.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Participants

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lilly Centre for Clinical Pharmacology, Singapore

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
  • Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
  • To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
  • To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion criteria

  • Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.
  • Have hemoglobin A1c (HbA1c) > 6.4% or 46 millimoles/mole (mmol/mol) at screening.
  • Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
  • Have had surgical treatment for obesity.
  • Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.

Treatment and study plan

LY4060874

Drug

Administered SC

Placebo

Drug

Administered SC

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 22 Weeks

    Number of participants with one or more TEAEs and SAEs.

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time (AUC) of LY4060874

    Time frame: PK: Part A: Baseline up to 13 weeks; Part B and C: Baseline up to 18 weeks

    PK: Area Under the Concentration Versus Time (AUC) of LY4060874

  2. PK: Maximum Observed Concentration of LY4060874

    Time frame: PK: Part A: Baseline up to 13 weeks; Part B and C: Baseline up to 18 weeks

    PK: Cmax of LY4060874

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Nov 29, 2024
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.